Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 27;21(13):4579.
doi: 10.3390/ijms21134579.

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

Stefania Cocco  1 , Michela Piezzo  1 , Alessandra Calabrese  1 , Daniela Cianniello  1 , Roberta Caputo  1 , Vincenzo Di Lauro  1 , Giuseppina Fusco  1 , Germira di Gioia  1 , Marina Licenziato  1 , Michelino De Laurentiis  1
Affiliations
Review

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

Stefania Cocco et al. Int J Mol Sci. .

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still the main therapeutic approach for this subgroup of patients, therefore, progress in the treatment of TNBC remains an important challenge. Data derived from molecular technologies have identified TNBCs with different gene expression and mutation profiles that may help developing targeted therapies. So far, however, only a few of these have shown to improve the prognosis and outcomes of TNBC patients. Robust predictive biomarkers to accelerate clinical progress are needed. Herein, we review prognostic and predictive biomarkers in TNBC, discuss the current evidence supporting their use, and look at the future of this research field.

Keywords: BRCA1/2; CSC; CTCs; HRR; PDL1; PI3KCA; PTEN; TILs; TNBC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bastien R.R., Rodríguez-Lescure Á., Ebbert M.T., Prat A., Munárriz B., Rowe L., Miller P., Ruiz-Borrego M., Anderson D., Lyons B., et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bmc Med. Genom. 2012;5:44. doi: 10.1186/1755-8794-5-44. - DOI - PMC - PubMed
    1. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007;13:4429–4434. doi: 10.1158/1078-0432.CCR-06-3045. - DOI - PubMed
    1. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011;121:2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Lehmann B.D., Jovanović B., Chen X., Estrada M.V., Johnson K.N., Shyr Y., Moses H.L., Sanders M.E., Pietenpol J.A. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE. 2016;11:e0157368. doi: 10.1371/journal.pone.0157368. - DOI - PMC - PubMed
    1. Rahim B., O’Regan R. AR Signaling in Breast Cancer. Cancers. 2017;9:21. doi: 10.3390/cancers9030021. - DOI - PMC - PubMed

Substances